Europa Trial

From Anvita Health Wiki

Contents 1 Introduction 2 More General Terms 3 Additional Terms 4 References

Introduction

• Study design:
• 12,218 patients with:

• stable coronary artery disease ( CAD)
• no heart failure

• perindopril target dose 8 mg QD vs. placebo
• standard CAD therapy
• mean follow-up of 4.2 years
• randomized study supported by manufacturer of perindopril

• Results:

• rate of cardiovascular death, nonfatal myocardial infarction or cardiac arrest with successful rescuscitation was significantly lower in perindopril group than placebo group (8% vs 10%)
• benefit evident even among patients taking:

• beta-blocker
• hypolipidemic agent
• calcium channel blocker

• benefit evident in diabetic patients
• perindopril lowered blood pressure by an average of:

• 5 mm Hg systolic
• 2 mm Hg diastolic

• improved outcomes noted in patients with or without hypertension

More General Terms

• clinical trial

Additional Terms

• PEACE study

References

- Journal Watch 23(22):175-76, 2003 EURopean trial On reduction of cardiac events with Perinopril in stable coronary Artery disease (EUROPA) Investigators, Lancet 362: 782 PMID: [1] EURopean trial On reduction of cardiac events with Perinopril in stable coronary Artery disease (EUROPA) trial